Systemic lupus erythematosus in a multiethnic US cohort (LUMINA L II): Relationship between vascular events and the use of hormone replacement therapy in postmenopausal women

Journal of Clinical Rheumatology

Volumn 13, Issue 5, 2007, Pages 261-265

  Fernández, Mónica ^a   Calvo Alén, Jaime ^a   Bertoli, Ana M ^a   Bastian, Holly M ^a   Fessler, Barri J ^a   McGwin Jr , Gerald ^b,c   Reveille, John D ^d   Vilá, Luis M ^e   Alarcón, Graciela S ^a  

^a University of Alabama at Birmingham   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c Kentucky   (United States)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

Hormone; Postmenopausal; Replacement; Vascular; Women

Indexed keywords

FOLLITROPIN; HORMONE; PHOSPHOLIPID ANTIBODY;

ADULT; ARTERY THROMBOSIS; ARTICLE; CLIMACTERIUM; COHORT ANALYSIS; CONTROLLED STUDY; ETHNICITY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES; VASCULAR DISEASE; VEIN THROMBOSIS;

ADULT; AFRICAN AMERICANS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MEXICAN AMERICANS; MIDDLE AGED; PERIPHERAL VASCULAR DISEASES; RISK FACTORS; UNITED STATES; VENOUS THROMBOSIS;

EID: 35148869629     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318156bbf5     Document Type: Article

References (30)

1. Sánchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-433.
2. Meier CR, Sturkenboom MC, Cohen AS, et al. Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus. J Rheumatol. 1998;25:1515-1519.
3. Cooper GS, Dooley MA, Treadwell EL, et al. Hormonal and reproductive risk factors for development of systemic lupus erythematosus. Arthritis Rheum. 2002;46:1830-1839.
4. Mok CC, Lau CS, Ho CT, et al. Safety of hormonal replacement therapy in postmenopausal patients with systemic lupus erythematosus. Scand J Rheumatol. 1998;27:342-346.
5. Arden NK, Lloyd ME, Spector TD, et al. Safety of hormone replacement therapy in systemic lupus erythematosus. Lupus. 1994;3:11-13.
6. Kreidstein S, Urowitz MB, Gladmann DD, et al. Hormonal replacement therapy in systemic lupus erythematosus. J Rheumatol. 1997;24:2149-2152.
7. Mok CC, Lau CS, Wong R. Use of exogenous estrogens in systemic lupus erythematosus. Semin Arthritis Rheum. 2001;30:426-435.
8. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953-962.
9. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
10. Mitchell JL, Walsh J, Wang-Cheng R, et al. Postmenopausal hormone therapy: a concise guide to therapeutic uses, formulations, risks, and alternatives. Prim Care. 2003;30:671-696.
11. Staren ED, Omer S. Hormone replacement therapy in postmenopausal women. Am J Surg. 2004;188:136-149.
12. Alarcon GS, Friedman AW, Straaton KV, et al. Systemic lupus erythematosus in three ethnic groups. III. A comparison of characteristics early in the natural history of the LUMINA cohort. Lupus in minority populations: nature vs. nurture. Lupus. 1999;8:197-209.
13. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17:2265-2281.
14. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrics. 1983;70:41-55.
15. Rubin DB. Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 1997;127:757-763.
16. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study. Am J Epidemiol. 1997;145:408-415.
17. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49-57.
18. Salpeter S, Walsh JM, Greyber E, et al. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19:791-804.
19. Herrington DM, Reboussin DM, Brosniham B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med. 2000;343:522-642.
20. Le Gal G, Gourlet V, Hogrel P, et al. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis. 2003;166:163-170.
21. Harman SM, Brinton EA, Clarkston T, et al. Is the WHI relevant to HRT started in the perimenopause? Endocrine. 2004;24:195-202.
22. Ward MM. Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum. 1999;42:338-346.
23. Toloza SMA, Uribe AG, McGwin G Jr, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004;50:3947-3957.
24. Simon JA, Hsia J, Cauley JA, et al. Postmenopausal hormone therapy and risk of stroke. The Heart and Estrogen-progestin Replacement Study (HERS). Circulation. 2001;103:638-642.
25. Paganini-Hill A, Ross RK, Henderson BE. Postmenopausal oestrogen treatment and stroke: a prospective study. BMJ. 1988;297:519-522.
26. Falkeborn M, Persson I, Terent A, et al. Hormone replacement therapy and the risk of stroke. Follow-up of a population-based cohort in Sweden. Arch Intern Med. 1993;153:1201-1209.
27. Finucane FF, Madans JH, Bush TL, et al. Decreased risk of stroke among postmenopausal hormone users. Results from a national cohort. Arch Intern Med. 1993;153:73-79.
28. Hendrix SL, Wassertheil-Smoller S, Johnson KC, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434.
29. Hess EV. Help for menopausal patients with lupus? Ann Intern Med. 2005;142:1014-1015.
30. NIH State of the Science Panel. National Institutes of Health State-of-the-Science Conference statement: management of menopause-related symptoms. Ann Intern Med. 2005;142:1003-1013.